Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Shaji K. Kumar, MD
The Impact of a Plant-Based Diet on Multiple Myeloma Prevention and Progression
Urvi A. Shah, MD, MS
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.